316
Participants
Start Date
July 31, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Placebo (for alirocumab)
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Alirocumab
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Lipid-Modifying Therapy (LMT)
Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Investigational Site Number 840817, Newington
Investigational Site Number 840853, New Windsor
Investigational Site Number 840822, Rochester
Investigational Site Number 840825, Pittsburgh
Investigational Site Number 840869, Philadelphia
Investigational Site Number 840803, Downington
Investigational Site Number 840804, Manassas
Investigational Site Number 840882, Norfolk
Investigational Site Number 840810, Weber City
Investigational Site Number 840502, Winston-Salem
Investigational Site Number 840852, Winston-Salem
Investigational Site Number 840885, Charleston
Investigational Site Number 840827, Mt. Pleasant
Investigational Site Number 840872, Anderson
Investigational Site Number 840813, Greer
Investigational Site Number 840850, Columbus
Investigational Site Number 840881, Port Orange
Investigational Site Number 840811, Oviedo
Investigational Site Number 840866, Coral Gables
Investigational Site Number 840805, Miami
Investigational Site Number 840867, Boca Raton
Investigational Site Number 840884, Boynton Beach
Investigational Site Number 840836, Clearwater
Investigational Site Number 840857, Birmingham
Investigational Site Number 840876, Montgomery
Investigational Site Number 840891, Mobile
Investigational Site Number 840837, Port Gibson
Investigational Site Number 840823, Paducah
Investigational Site Number 840831, Columbus
Investigational Site Number 840809, Willoughby Hills
Investigational Site Number 840846, Cincinnati
Investigational Site Number 840899, Cincinnati
Investigational Site Number 840860, Kettering
Investigational Site Number 840896, Indianapolis
Investigational Site Number 840894, Michigan City
Investigational Site Number 840838, Mishawaka
Investigational Site Number 840832, Southfield
Investigational Site Number 840890, Battle Creek
Investigational Site Number 840839, Edina
Investigational Site Number 840888, Minneapolis
Investigational Site Number 840898, Evanston
Investigational Site Number 840842, Chicago
Investigational Site Number 840847, Morton
Investigational Site Number 840814, Jefferson City
Investigational Site Number 840802, New Orleans
Investigational Site Number 840858, Eunice
Investigational Site Number 840826, Jonesboro
Investigational Site Number 840818, Norman
Investigational Site Number 840877, Houston
Investigational Site Number 840841, Houston
Investigational Site Number 840889, Tomball
Investigational Site Number 840830, San Antonio
Investigational Site Number 840854, San Antonio
Investigational Site Number 840883, San Antonio
Investigational Site Number 840868, Corpus Christi
Investigational Site Number 840878, Bountiful
Investigational Site Number 840819, Orem
Investigational Site Number 840863, Salt Lake City
Investigational Site Number 840865, Glendale
Investigational Site Number 840851, Los Angeles
Investigational Site Number 840862, Torrance
Investigational Site Number 840886, Tarzana
Investigational Site Number 840870, Burbank
Investigational Site Number 840893, Vista
Investigational Site Number 840845, Los Gatos
Investigational Site Number 840801, San Jose
Investigational Site Number 840844, Sacramento
Investigational Site Number 840812, Eugene
Investigational Site Number 840895, Fort Lauderdale
Investigational Site Number 840820, Hialeah
Investigational Site Number 840816, West Palm Beach
Investigational Site Number 840840, Eagle
Investigational Site Number 840833, Sparks
Investigational Site Number 840824, Cary
Investigational Site Number 840880, Smithfield
Investigational Site Number 840855, Salisbury
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY